Zobrazeno 1 - 10
of 2 572
pro vyhledávání: '"D'angelo V"'
Autor:
Mario Valenti, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Andrea Carugno, Marco Campoli, Carlo G. Carrera, Francesca M. Gaiani, Davide Strippoli, Federica Mola, Angelo V. Marzano, Nicola Zerbinati, Anna Minuti, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 11, Pp 2987-2997 (2024)
Abstract Introduction Guselkumab, a human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown efficacy in psoriasis and psoriatic arthritis. However, long-term real-world data on its effectiveness in patients with inade
Externí odkaz:
https://doaj.org/article/fd8bd851d8bd47e3b07fbd568cfba933
Autor:
Rashed Al-Khudairi, MBBS, Alexandros Maris, MD, MSc, Ahmed Blehadj, MD, Angelo V. Vasiliadis, MD, PhD
Publikováno v:
Radiology Case Reports, Vol 19, Iss 10, Pp 4485-4488 (2024)
Osteopoikilosis, a sclerosing bone dysplasia, is an asymptomatic incidental finding characterised by multiple bone islands. Although it requires no treatment there can be diagnostic uncertainty as appearances can be similar to osteoblastic metastases
Externí odkaz:
https://doaj.org/article/fdc5f05dcfc946658ac87314c36fce30
Autor:
Alexandros Maris, MD, MSc, PhD, Rashed Al-Khudairi, MBBS, Alexander Maslaris, MD, Angelo V. Vasiliadis, MD, PhD
Publikováno v:
Radiology Case Reports, Vol 19, Iss 10, Pp 4158-4162 (2024)
Spontaneous osteonecrosis of the knee (SONK) is a poorly understood but debilitating disease, that is a common cause of unilateral acute knee pain and swelling. The term “SONK” has been replaced by the term “subchondral insufficiency fracture
Externí odkaz:
https://doaj.org/article/8dc92d523f2846ef816dfe5bd9fca9f5
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 2591-2598 (2015)
Maria Teresa Triscari,1 Palmira Faraci,2 Dario Catalisano,3 Valerio D’Angelo,1 Viviana Urso1 1Laboratory for Psychosomatic Disorders, Local Health Trust, Palermo, Italy; 2Faculty of Human and Social Sciences, University of Enna “Kore”, Enna, It
Externí odkaz:
https://doaj.org/article/7845ebcdd7d14e14b8c82b84a843fcf3
Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors
Autor:
Francesca Barei, Paolo Calzari, Luca Valtellini, Alessandra Chiei Gallo, Gabriele Perego, Simona Tavecchio, Martina Zussino, Angelo V. Marzano, Silvia Ferrucci
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Background Atopic dermatitis (AD) profoundly impacts patients’ lives, necessitating long-term systemic treatments.Methods This retrospective study involved 709 severe AD patients receiving dupilumab. Drug survival (DS) was analyzed using Kaplan-Mei
Externí odkaz:
https://doaj.org/article/c3cedb4b4eb94bc39837702e58b0f53f
Autor:
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Pina Brianti, Giovanna Brunasso, Martina Burlando, Anna E. Cagni, Marzia Caproni, Carlo G. Carrera, Andrea Carugno, Francesco Caudullo, Aldo Cuccia, Paolo Dapavo, Eugenia V. Di Brizzi, Valentina Dini, Francesca M. Gaiani, Paolo Gisondi, Claudio Guarneri, Claudia Lasagni, Gaetano Licata, Francesco Loconsole, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Maria L. Musumeci, Diego Orsini, Simone Ribero, Valentina Ruffo Di Calabria, Francesca Satolli, Davide Strippoli, Massimo Travaglini, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Purpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab
Externí odkaz:
https://doaj.org/article/50011e4f4d42477e96cf16f9d602b59b
Autor:
Feliciana Mariotti, Anna Pira, Naomi De Luca, Anna Rita Giampetruzzi, Filomena Russo, Amilcare Cerri, Giulia Gasparini, Emanuele Cozzani, Angelo V. Marzano, Emiliano Antiga, Marzia Caproni, Pietro Quaglino, Marco Carrozzo, Biagio Didona, Giovanni Di Zenzo
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundBullous pemphigoid (BP) and mucous membrane pemphigoid (MMP) are rare autoimmune blistering disorders characterized by autoantibodies (autoAbs) targeting dermo-epidermal junction components such as BP180 and BP230. The differential diagnosi
Externí odkaz:
https://doaj.org/article/868c5d6fb4664c848917fa285871a686
Autor:
Luigi Gargiulo, Luciano Ibba, Alessandra Narcisi, Silvia Giordano, Carlo A. Maronese, Fabrizio Martora, Federica Repetto, Giovanni Paolino, Anna Balato, Martina Burlando, Paolo Dapavo, Valentina Dini, Claudio Guarneri, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Antonio Costanzo, Mario Valenti
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 4 (2024)
Introduction: Psoriasis and hidradenitis suppurativa (HS) are chronic inflammatory diseases with significant overlap in their immunologic pathways, which involve cytokines such as tumor necrosis factor-alfa, interleukin (IL)-17, and IL-23. Current tr
Externí odkaz:
https://doaj.org/article/8bd8149f86274025acc4efd6ef6b99f0
Autor:
Silvia Ferrucci, Maddalena Napolitano, Francesca Barei, Luca Valtellini, Angelo V. Marzano, Cataldo Patruno, Emanuela Martina, Anna Campanati
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 2, Pp 731-734 (2024)
Externí odkaz:
https://doaj.org/article/843525a4e52249cf9c7891143217bde6
Autor:
Mario Valenti, Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Paolo Dapavo, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Diego Orsini, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1649-1657 (2024)
Abstract Introduction The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safet
Externí odkaz:
https://doaj.org/article/2457ce851f3b4d589b890cf51ca53d3c